文献速递神经肌肉病

低剂量A型肉毒毒素改善多发性硬化症未行导尿患者的泌尿症状

Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS.
PubMed 文献 · Neurology · 2018-07-20

这项随机双盲III期研究纳入多发性硬化症伴神经源性逼尿肌过度活动所致尿失禁的未行导尿患者,比较逼尿肌内注射A型肉毒毒素100 U(n=66)与安慰剂(n=78)的疗效与安全性。第6周时,A型肉毒毒素组尿失禁发作减少显著优于安慰剂组,生活质量改善更明显,但清洁间歇导尿率较高。

要点

  • A型肉毒毒素100 U组第6周尿失禁发作减少3.3次/天,安慰剂组减少1.1次/天,差异显著(p<0.001)。
  • A型肉毒毒素组53.0%患者实现100%尿失禁减少,安慰剂组为10.3%(p<0.001)。
  • A型肉毒毒素组清洁间歇导尿率为15.2%,安慰剂组为2.6%。

核心结论

  • 在未行导尿的多发性硬化症伴神经源性逼尿肌过度活动患者中,逼尿肌内注射A型肉毒毒素100 U可显著改善尿失禁和生活质量,且清洁间歇导尿率低于既往报道的200 U。

研究设计与样本

  • 随机双盲III期研究,纳入多发性硬化症伴神经源性逼尿肌过度活动所致尿失禁的未行导尿患者,A型肉毒毒素100 U组66例,安慰剂组78例,经膀胱镜行逼尿肌内注射。

主要发现

  • 第6周时,A型肉毒毒素组尿失禁发作减少3.3次/天,安慰剂组减少1.1次/天(p<0.001,主要终点)。
  • A型肉毒毒素组53.0%患者实现100%尿失禁减少,安慰剂组为10.3%(p<0.001)。
  • A型肉毒毒素组尿动力学指标改善显著(p<0.01)。
  • A型肉毒毒素组I-QOL总分改善40.4分,安慰剂组改善9.9分(p<0.001),约为最小重要差异(+11分)的3倍。
  • 最常见不良事件为尿路感染(25.8%);清洁间歇导尿率A型肉毒毒素组为15.2%,安慰剂组为2.6%。

关键数值与推荐

  • A型肉毒毒素100 U组尿失禁发作减少3.3次/天 vs 安慰剂组减少1.1次/天(p<0.001)。
  • A型肉毒毒素组53.0% vs 安慰剂组10.3%实现100%尿失禁减少(p<0.001)。
  • A型肉毒毒素组I-QOL改善40.4分 vs 安慰剂组9.9分(p<0.001)。
  • 清洁间歇导尿率A型肉毒毒素组15.2% vs 安慰剂组2.6%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of onabotulinumtoxinA 100 U in noncatheterizing patients with multiple sclerosis (MS) with urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO). METHODS: In this randomized, double-blind phase III study, patients received onabotulinumtoxinA 100 U (n = 66) or placebo (n = 78) as intradetrusor injections via cystoscopy. Assessments included changes from baseline in urinary symptoms, urodynamics, and Incontinence-Quality of Life (I-QOL) total score. Adverse events (AEs) were assessed, including initiation of clean intermittent catheterization (CIC) due to urinary retention. RESULTS: OnabotulinumtoxinA vs placebo significantly reduced UI at week 6 (-3.3 episodes/day vs -1.1 episodes/day, p < 0.001; primary endpoint). Significantly greater proportions of onabotulinumtoxinA-treated patients achieved 100% UI reduction (53.0% vs 10.3%, p < 0.001). Significant improvements in urodynamics (p < 0.01) were observed with onabotulinumtoxinA. Improvements in I-QOL score were significantly greater with onabotulinumtoxinA (40.4 vs 9.9, p < 0.001) and ≈3 times the minimally important difference (+11 points). The most common AE was urinary tract infection (25.8%). CIC rates were 15.2% for onabotulinumtoxinA and 2.6% for placebo. CONCLUSION: In noncatheterizing patients with MS, onabotulinumtoxinA 100 U significantly improved UI and quality of life with lower CIC rates than previously reported with onabotulinumtoxinA 200 U. CLINICALTRIALSGOV IDENTIFIER: NCT01600716. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that compared with placebo, 100 U onabotulinumtoxinA intradetrusor injections significantly reduce UI and improve quality of life in noncatheterizing patients with MS and NDO.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Tullman M, Chartier-Kastler E, Kohan A, et al. Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS. Neurology. 2018. PMID: 30030330. doi:10.1212/WNL.0000000000005991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。